The chemotherapy-induced neutropenia causes mortality and morbidity at a significant rate (Aapro et al., 2011; Fontanella et al., 2014). Fever is frequently observed during chemotherapy-induced neutropenia. Neutropenia-related fever could be encountered for at least once in 10-50% of patients with solid tumor and >80% of patients with hematological malignancy (Freifeld et al., 2011). In patient...

BACKGROUND Febrile neutropenia (FN) is generally a complication of cancer chemotherapy. OBJECTIVES We retrospectively evaluated the febrile neutropenia episodes and their outcomes with respect to modification rates of non-carbapenem-based empirical antibacterial therapy and vancomycin-resistant enterococcus (VRE) colonisation that caused to VRE bacteremia in patients with hematological malign...

Objective: We aimed to investigate the effectiveness of quick Sequential Organ Failure Assessment (qSOFA), Multinational Association for Supportive Care in Cancer (MASCC), and Clinical Index Stable Febrile Neutropenia (CISNE) scores identifying low-risk febrile neutropenia patients among with chemotherapy-associated emergency department setting.
 Material Method: The risk were calculated d...

Aim: One method to deal with febrile neutropenia is the use of granulocyte colony stimulating factors (G-CSFs). Pegfilgrastim or Filgrastim injection can lead to a reduction in febrile neutropenia and severe neutropenia in patients receiving chemotherapy. This study aimed to compare the cost-effectiveness of using Pegfilgrastim, 3-day Filgrastim and 1-day Filgrastim medication strategies for th...